Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer – Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor...
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting – Bavdegalutamide demonstrated a 46% PSA50 rate in patients with...
Kit Check’s Bluesight® for Controlled Substances is Named Best in KLAS for the 3rd Consecutive YearFor the third year running, Bluesight for Controlled Substances takes top marks in all product categories and receives a score of 90.9 out of 100 Arlington, VA–February,...
Kit Check Launches Webinar Series Focused on RFID Innovation in HealthcareKit Check launches educational webinar series focused on supporting ASHP’s Enhancing Adoption of RFID Technology Research Grant Alexandria, VA, January 20, 2022: Kit Check, the market leader in...
Kyruus Announces Record-Breaking Customer Growth in 2021, Welcoming HealthSparq and Connecting Millions of People with CareLeading Digital Health Company Expands Provider and Payer Customer Base as Demand for Patient Access Solutions Accelerates Across the Healthcare...
Recent Comments